Data / Drug companies / Bromocriptine mesylate
Bromocriptine mesylate: 9 companies and 10 products in the FDA NDC directory
Bromocriptine mesylate is listed in the FDA National Drug Code Directory by 9 companies, with 10 products in commercial distribution. 6 of the products (60.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; capsule, and the newest product started marketing on June 12, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 10
- Generic (ANDA) products
- 6 (60.0%)
- Application numbers
- 6
- Routes
- Oral
- Brand names
- Cycloset
- openFDA record search
- api.fda.gov
Companies that list bromocriptine mesylate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Ani Pharmaceuticals, Inc. | 2 | tablet; capsule | New drug applications (NDA) | April 6, 2026 |
| American Health Packaging | 1 | tablet | New drug applications (NDA) | June 12, 2026 |
| Avvisto Therapeutics LLC | 1 | tablet | New drug applications (NDA) | May 23, 2024 |
| Mylan Pharmaceuticals Inc. | 1 | capsule | Generic drugs (ANDA) | June 17, 2013 |
| Padagis US LLC | 1 | tablet | Generic drugs (ANDA) | April 1, 2014 |
| Remedyrepack Inc. | 1 | tablet | Generic drugs (ANDA) | April 24, 2026 |
| Sandoz Inc | 1 | tablet | Generic drugs (ANDA) | January 13, 1998 |
| Zydus Lifesciences Limited | 1 | capsule | Generic drugs (ANDA) | January 23, 2009 |
| Zydus Pharmaceuticals USA Inc. | 1 | capsule | Generic drugs (ANDA) | January 23, 2009 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 6 | 60% |
| Capsule | 4 | 40% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 6 | 60% |
| New drug applications (NDA) | 4 | 40% |
Pharmacologic classes
| Class | Products |
|---|---|
| Ergot Derivative | 10 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.